Gamma delta (γδ) T cells hold significant potential for unmet medical needs. Yet they are more challenging to source than other T cells, representing as little as 1% to 5% of the total CD3+ T ...

New York- and Alabama-based IN8bio is leveraging gamma-delta (γδ) T cell biology to merge innate and adaptive immune capabilities against cancer. Has some of the early excitement in the cell ...

Despite their minority status within the T cell community, gamma-delta T cells are increasingly recognized for their dual ...

FLORIDA: The significance of gamma-delta T cells in 33 different cancer types is revealed in a recent study that was ...

GammaDelta Therapeutics has developed a pipeline of novel allogeneic cell therapies based on its Vδ1+ γδ T cell platforms for the treatment of solid tumors and beyond. Gamma delta (γδ) T ...

(Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will present at NobleCon20 - Noble ...

Join the 3rd Gamma Delta T Therapies Summit to learn and network ... globally accessible cell therapy for solid tumors. Enhance cytotoxicity, discover novel targets, engineer stealth, and ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimm ...

IN8bio (INAB) presented results from the fully enrolled Phase 1 trial of INB-200 in a plenary oral presentation at the 29th Annual Meeting of ...

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming plenary oral presentation at the 29 th Annual ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...